大华继显:重申石药集团(1093.HK)买入评级 目标价上调至12.3港元
石药集团(1093.HK)公布去年全年业绩,大华继显发表研究报告指,公司去年全年收入及纯利分别增上12.8%及38.9%,而核心盈利按年升18%,表现符合预期,认为公司具有强劲的产品管线,短期内亦有数只具有潜力的药品正处于审评待批阶段,公司前景明朗,将目标价由10.76港元上调至12.3港元,重申买入评级。
该行指,公司创新药产品恩必普价格受压已反映于现时股价,预期恩必普未来销售增长将会走强,未来具有潜力但正处于审评待批阶段的药品将于2022年成为增长动力,公司去年在研发方面投入28.9亿元人民币,按年增加约44.5%,认为多元化的创新管线将会带动公司长期盈利增长。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.